Model Card

Basic identifying metadata about the model artifact, including version, type, and responsible developers.

• Model Name & Version: Unique identifier and semantic versioning (e.g., pneumonia-cxr-v2.3)
• Model Architecture: Specifies the underlying algorithm (e.g., ResNet-50, Vision Transformer)
• Development Organization: Entity responsible for training and maintenance
• Release Date: Timestamp of when the model artifact was finalized
• Contact Information: Designated point of contact for inquiries or incident reporting

This section establishes provenance and accountability, critical for audit trails in federated networks where multiple institutions contribute to training.

A precise delineation of the clinical or operational scenarios for which the model was designed, validated, and approved.

• Primary Use Case: The specific diagnostic or predictive task (e.g., detecting consolidation in frontal chest radiographs)
• Intended User: Qualified radiologists, clinical decision support systems, or triage workflows
• Deployment Context: In-hospital PACS integration, edge inference on portable X-ray units, or federated inference across nodes
• Out-of-Scope Applications: Explicitly prohibited uses (e.g., pediatric patients if trained only on adults, or standalone diagnosis without human review)

Misuse prevention is a core regulatory expectation under FDA's SaMD framework and EU AI Act Article 13 transparency obligations.

Quantitative performance metrics disaggregated across relevant demographic and clinical subgroups to surface potential disparities.

• Aggregate Metrics: Overall accuracy, sensitivity, specificity, AUC-ROC, and F1 score on held-out test sets
• Disaggregated Performance: Metrics stratified by age group, biological sex, race/ethnicity, comorbidity status, and imaging device manufacturer
• Confidence Intervals: 95% CIs for all reported metrics to communicate statistical uncertainty
• Benchmark Comparisons: Performance relative to existing clinical standards or human reader studies

This section operationalizes fairness evaluation and directly supports compliance with HIPAA's non-discrimination provisions and FDA's guidance on algorithmic bias.

A comprehensive description of the datasets used during model development, including their composition, collection methodology, and known limitations.

• Data Sources: Enumerated institutions, public repositories, and federated nodes contributing training samples
• Demographic Composition: Distribution of age, sex, race, and clinical conditions within the training corpus
• Sample Size: Total number of cases, with breakdowns by positive/negative class and subgroup
• Preprocessing Steps: Normalization, augmentation, de-identification pipeline details, and exclusion criteria
• Known Gaps: Acknowledged underrepresentation (e.g., rare disease phenotypes, specific demographic strata)

In federated learning contexts, this section must also disclose data heterogeneity across silos and any non-IID characteristics that may affect global model generalizability.

A candid assessment of potential harms, failure modes, and fairness implications identified during the model's development and validation lifecycle.

• Identified Biases: Documented performance disparities across demographic subgroups with root-cause hypotheses
• Failure Mode Analysis: Known clinical edge cases where model confidence is unreliable (e.g., atypical presentations, rare comorbidities)
• Privacy Risks: Residual membership inference or model inversion vulnerability assessments, especially relevant in federated settings
• Mitigation Strategies: Applied interventions such as re-weighting, adversarial debiasing, or differential privacy noise calibration
• Monitoring Recommendations: Suggested real-world performance surveillance protocols and drift detection thresholds

This section aligns with Algorithmic Impact Assessment requirements and the NIST AI Risk Management Framework's Map-Measure-Manage paradigm.

Detailed statistical breakdowns that go beyond aggregate evaluation to examine intersectional performance and model behavior characteristics.

• Intersectional Analysis: Performance metrics for compound demographic categories (e.g., Black women over 65 with diabetes) to uncover hidden stratification
• Calibration Curves: Reliability diagrams showing whether predicted probabilities align with observed frequencies across subgroups
• Confusion Matrices: Full error breakdowns (true/false positives/negatives) per subgroup to distinguish error types
• Uncertainty Quantification: Epistemic vs. aleatoric uncertainty estimates, critical for clinical decision support where abstention may be appropriate

This granularity enables re-identification risk assessment and supports privacy budget accounting when differential privacy is applied during federated training rounds.

A structured evaluation framework used to identify and mitigate potential discriminatory harms and safety risks of an automated decision-making system before deployment. While a model card discloses what a model is, the impact assessment justifies why it should exist.

• Mandated by the EU AI Act for high-risk systems
• Evaluates necessity, proportionality, and fundamental rights impact
• Feeds directly into the limitations and ethical considerations sections of a model card

Feature attribution methods that decode opaque neural networks, ensuring automated decisions can be audited and understood by human operators. Model cards rely on XAI outputs to populate their evaluation results and fairness analysis sections.

• SHAP and LIME provide per-prediction explanations
• Integrated Gradients maps input features to output sensitivity
• Explainability metrics are increasingly required in FDA-cleared SaMD submissions

A mandatory risk assessment required by GDPR Article 35 for high-risk processing. The DPIA documents what personal data is used, how it flows, and what mitigations are in place—information that directly informs the data provenance and privacy disclosures in a model card.

• Required when processing special category data (health, biometrics)
• Must be completed prior to training
• Complements model cards for joint regulatory submission packages

A chronological, verifiable documentation trail recording the sequence of custody, control, transfer, and analysis of clinical data and model artifacts. Model cards serve as the summary endpoint of this chain, attesting that every transformation from raw data to trained weights is traceable.

• Uses cryptographic hashing and tamper-evident logging
• Essential for FDA's Good Machine Learning Practice (GMLP)
• Links data lineage to specific model versions

The statistical probability that an anonymized patient record can be correctly linked back to a specific individual using auxiliary information. Model cards must disclose this residual risk, especially when models are trained on pseudonymized rather than fully anonymized data.

• Measured via k-anonymity, l-diversity, and differential privacy guarantees
• Informs the privacy budget expenditure documented in the card
• Critical for HIPAA Safe Harbor compliance attestations

The process of auditing and validating model performance across distributed nodes without centralizing test data. In a federated context, the model card must aggregate evaluation metrics from heterogeneous local datasets, requiring careful documentation of distribution shifts.

• Addresses bias across demographic subgroups at different sites
• Uses federated XAI to surface site-specific failure modes
• Essential for cross-silo healthcare deployments where data never leaves the institution